Trials
3 active
19 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet”In the company’s words, NCT04639180 on ClinicalTrials.gov
- Tested for
- Gastric Cancer, Hepatocellular Carcinoma (HCC), Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
- Main trialPhase 3
- “This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.”In the company’s words, NCT04342910 on ClinicalTrials.gov
- Other names
- Apatinib · Apatinib Mesylate
Other drugs for Gastric Cancer
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up1
- Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Apr 2026 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | |
| Phase 3Active, not recruiting | 31 Jul 2026 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | |
| Phase 2Not yet recruiting | Jul 2027 | A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma | |
| Phase 3Completed | 15 Dec 2017 | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | |
| Phase 3Terminated | 29 Dec 2021 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | |
| Phase 3Completed | 8 Feb 2022 | A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC | |
| Phase 3Terminated | 14 Apr 2023 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. | |
| Phase 3Completed | 7 Jun 2023 | A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy | |
| Phase 2Completed | Jul 2013 | A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma | |
| Phase 2Completed | 25 Nov 2020 | A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer | |
| Phase 2Completed | 31 Mar 2021 | A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | |
| Phase 2Completed | 4 Aug 2021 | SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy | |
| Phase 2Completed | 22 Apr 2022 | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | |
| Phase 2Terminated | 29 Jun 2023 | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | |
| Phase 1Completed | 6 Jul 2020 | A Food Effect Study of Apatinib Mesylate in Healthy Subjects | |
| Phase 1Unknown | Feb 2021 | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | |
| Phase 1Completed | 3 Apr 2021 | A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects | |
| Phase 1Completed | 20 May 2021 | A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects | |
| Phase 1Completed | 22 Aug 2021 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026